Who are Klaron's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trimethoprim, Gentamicin, Wellcovorin, Co-trimoxazole 20, methotrexate + misoprostol, AZATHIOPRINE or METHOTREXATE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sulfacetamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Klaron — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Klaron (SULFACETAMIDE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfonamide Antibacterial. Area: Infectious Disease.

marketed Sulfonamide Antibacterial Dihydrofolate reductase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Klaron (SULFACETAMIDE) — Merck & Co..

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Klaron TARGET	SULFACETAMIDE	Merck & Co.	marketed	Sulfonamide Antibacterial	Dihydrofolate reductase	1945-01-01
Trimethoprim	TRIMETHOPRIM	Dr Reddys Labs Sa	marketed	Sulfonamide Antimicrobial [EPC]	Dihydrofolate reductase	1973-01-01
Gentamicin	Gentamicin Sulfate	Merck & Co.	marketed	gentamicin	Dihydrofolate reductase	1970-01-01
Wellcovorin	leucovorin	Pfizer Japan Inc	marketed	Folate Analog	Dihydrofolate reductase	1952-01-01
Co-trimoxazole 20	Co-trimoxazole 20	Khon Kaen University	marketed	Sulfonamide antibiotic combination	Dihydropteroate synthase and dihydrofolate reductase
methotrexate + misoprostol	methotrexate + misoprostol	Wiebe, Ellen, M.D.	marketed	Antimetabolite + gastroprotective agent combination	Dihydrofolate reductase (methotrexate); prostaglandin E1 receptor (misoprostol)
AZATHIOPRINE or METHOTREXATE	AZATHIOPRINE or METHOTREXATE	Prof. Arie Levine	marketed	Immunosuppressive agents / Antimetabolites	Hypoxanthine-guanine phosphoribosyltransferase (HGPRT) for azathioprine; Dihydrofolate reductase (DHFR) for methotrexate

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfonamide Antibacterial class)

Merck & Co. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Klaron — Competitive Intelligence Brief. https://druglandscape.com/ci/sulfacetamide. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing